Alofanib Stomach cancer therapy drug

Main articles:

• Cancer (cancer)
• Stomach cancer
• Treatment of stomach cancer

2022: Development of the drug "Alofanib"

The R-Farm Group of Companies and the Rusfarmtech Research Company announced on April 12, 2022 the signing of a global license agreement for the development and commercialization of the antitumor drug Alofanib, designed for the treatment of stomach cancer and a number of other oncological diseases.

As part of the agreement between R-Pharm and Rusfarmtech, it is planned to conduct phase II and III clinical studies, register the drug in the Russian Federation, as well as organize its production at the facilities of the R-Pharm group of companies.

The drug Alofanib refers to fibroblast growth factor receptor inhibitors - a promising class of drugs for the treatment of cancer. Alofanib is the first of the class of allosteric inhibitor of the FGFR2 receptor, which provides high selectivity to the target, and this allows us to expect high performance and safety indicators.

During phase I Alofanib studies involving patients with the most severe, fourth stage gastric cancer, who received three or more lines of therapy before inclusion in the study, high performance rates were achieved.

Alofanib has shown positive efficacy results with significantly less toxicity than many other drugs. This makes it attractive to use it with combinations of existing drugs or after chemotherapy. As of April 2022, standard drugs show an increase in life expectancy in patients with severe stage up to four months, and control of the disease can be achieved in less than half of patients. Consequently, our positive results indicate the need to continue studying Alofanib, "said the first author of the study, chairman of the Russian Society of Clinical Oncology, Professor Sergey Tyulyandin.

We expect Alofanib to enter the market within three years, before the end of 2025. It is assumed that Russian patients will be able to receive therapy with this innovative drug under the program of state guarantees of medical care, "said Anastasia Batrak, vice president of strategic marketing at R-Farm.

One of the goals of the R-Farm group of companies in the long term will be to register the drug in foreign markets.